Compare Corning Incorporated (GLW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Sana Biotechnology Inc — how do they compare? Corning Incorporated trades at $156.69 (market cap $131.65B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Corning Incorporated is far larger — about 157.3× Sana Biotechnology Inc's market cap, and Corning Incorporated pays a 0.73% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Sana Biotechnology Inc for 23 Days on average.
| GLW | SANA | |
|---|---|---|
Market Cap | $131.65B | $836.71M |
Volume | 8,992,522 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $255.79 | $5.92 |
52-Week Low | $78.03 | $2.68 |
Typical Hold Time | 36 Days | 23 Days |
Enterprise Value | $138.52B | $749.96M |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $152.81, down 6.37% amid a bearish technical signal, though it recently secured a significant $3 billion fiber supply deal with AT&T. The company shows strong earnings momentum with three consecutive quarterly beats and improved 2025 financials, including revenue growth to $15.63B and net income of $1.60B. Valuation ratios remain elevated with a P/E of 70.43, while analyst consensus is bullish with a $171.25 price target.
The outlook is mixed: the AT&T deal and earnings strength support growth, but high valuation and a bearish technical picture pose risks. Investors should weigh the company's positioning in AI-driven infrastructure against potential volatility from patent litigation and competitive pressures.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
